drugset / Trial / NCT07283705
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Timeline
- Start
- 2026-05-18
- Primary completion
- 2029-10-01
- Completion
- 2031-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986504 | Unknown | — | Oral |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |